{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-22-000066","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.441291+00:00","generated_at":"2026-06-22T08:35:11.275729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira Q3 revenue up 31% to $167.5M, GAAP net loss $0.7M; EXPAREL sales $132.6M, patent to 2041","bullets":["Total revenues $167.5M (+31% YoY); EXPAREL $132.6M (+9%), ZILRETTA $26.5M.","GAAP net loss $0.7M ($0.02 loss/share) vs prior-year net income $17.7M ($0.40).","Non-GAAP net income $29.9M ($0.65/share); adjusted EBITDA $55.2M vs $48.1M.","New EXPAREL composition patent (No. 11,452,691) expires Jan 2041; positive Phase 3 lower extremity nerve block results.","CHMP positive opinion for pediatric EXPAREL use; encouraging Phase 1 data for PCRX-201 gene therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-22-000066","json":"https://secwatch.observer/filing/0001396814-22-000066.json","markdown":"https://secwatch.observer/filing/0001396814-22-000066.md","text":"https://secwatch.observer/filing/0001396814-22-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/0001396814-22-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/pcrx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:35:11.275729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"897767e4b04c413cdd4eba0795613fe77d0ba9d7","claim":"Pacira BioSciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $167.5 million, net income $0.7 million, or $(0.02) per share (basic and diluted), EPS $(0.02) per share (basic and diluted).","evidence_excerpt":"in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2022 Financial Results -- Third quarter revenue of $167 million, increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, FL, November 3, 2022 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/0001396814-22-000066-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$167.5 million"},{"label":"Net income","value":"$0.7 million, or $(0.02) per share (basic and diluted)"},{"label":"EPS","value":"$(0.02) per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}